Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results
Rein Therapeutics Reports Preliminary 12-Week Blinded Phase 2 RENEW Data For LTI-03 In IPF Patients; Study Achieves 75% Enrollment, With 90 Patients Randomized To Date; On Track To Report Topline Data In 2027
Rein Therapeutics Q3 EPS $(0.06) Beats $(0.10) Estimate
Rein Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
Rein Therapeutics To Present Data On Inhaled LTI-03 For Idiopathic Pulmonary Fibrosis At European Respiratory Society 2026 Congress
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
FDA Grants Rein Therapeutics Fast Track Designation For LTI-03
HC Wainwright & Co. Reiterates Buy on Rein Therapeutics, Maintains $8 Price Target
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Rein Therapeutics Q2 EPS $(0.10) Beats $(0.17) Estimate
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
Rein Therapeutics Begins Enrolling Patients In Phase 2 RENEW Trial
Maxim Group Initiates Coverage On Rein Therapeutics with Buy Rating, Announces Price Target of $4
Rein Therapeutics Inc. (RNTX) Shareholder/Analyst Call Prepared Remarks Transcript
All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
HC Wainwright & Co. Maintains Buy on Rein Therapeutics, Lowers Price Target to $8
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.